|
Xoma (WKN: 871239)
Die Insider haben gestern zugeschlagen!!! 
185k Common Shares zu 0,76$
app.quotemedia.com/quotetools/showFiling.go
app.quotemedia.com/quotetools/showFiling.go
app.quotemedia.com/quotetools/showFiling.go
app.quotemedia.com/quotetools/showFiling.go
app.quotemedia.com/quotetools/showFiling.go
www.finviz.com/chart.ashx?t=XOMA&ta=0&p=m&s=l" style="max-width:560px" />
www.finviz.com/chart.ashx?t=XOMA&ta=0&p=w&s=l" style="max-width:560px" />
www.finviz.com/chart.ashx?t=XOMA&ta=1&p=d&s=l" style="max-width:560px" />
diese hat auch die Kursexplosion vor 8-Tagen eingeleitet (man beachte auch die Umsätze) , die Konsolidierung scheint abgeschlossen zu sein. Jetzt wieder die Chance bei der nächsten Kaufwelle dabei zu sein (ausgelöst durch die Insiderkäufe).
app.quotemedia.com/quotetools/newsStoryPopup.go
und hier mehr zum Thema:
Nasdaq Day-Chart USA
de.advfn.com/...art&s=N%5EXOMA&p=0&t=16&vol=1" style="max-width:560px" alt="Xoma" />
May 26, 2009 (U.S. Equity News) --
Biotechnology industry alert provided by U.S. Equity News. Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announce that the scientific team is preparing to significantly ramp up the number of genetic insertions performed in the month of May. The team anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date. ``We are now entering the next phase in which the team is reallocating recourses to genetic insertion,'' said CEO Kim Thompson. ``This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.''
Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (NasdaS: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics' cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure.
XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the following presentations related to its XOMA 052 anti-interleukin-1 (IL-1) beta antibody will take place at the American Diabetes Association 69th Scientific Sessions, to be held at the Morial Convention Center in New Orleans, Louisiana from June 5 to 9.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that updated interim data from the Company's ongoing Phase 2 clinical trials in frontline acute myeloid leukemia (AML) and platinum-resistant ovarian cancer and its Phase 1b/2 clinical trial in relapsed/refractory AML will be presented during the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting in Orlando, Florida, which begins May 29, 2009. Following are the details on each of these data presentations.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
Contact: U.S. Equity News Tel: (626) 961-8039 Email: info@usequitynews.comNewstex ID: 35283714
Source: US Equity News (May 26, 2009 - 2:33 PM EDT)
News by QuoteMedia
app.quotemedia.com/quotetools/newsStoryPopup.go
www.otcbb.com/asp/quote_module.asp
Fazit: Bevor man sich auf irgendwelche Insolvenz-Zocks einlässt sollte man genau lesen....
gestern nachbörslich weiter gestiegen, bis 1,38$...
www.finviz.com/chart.ashx?t=XOMA&ta=1&p=d&s=l" style="max-width:560px" />
Das interessiert am Montag nicht nach den aktuellen News von gestern (Samstag) !!! IMO
XOMA Presents Phase 1 Diabetes Trial Data
Written by Staff and Wire Reports Saturday, 06 June 2009 14:16 biomedreports.com/articles/latest-news/...etes-trial-data.html
www.finviz.com/chart.ashx?t=XOMA&ta=1&p=d&s=l" style="max-width:560px" />
|
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 92 | Bausch Health - ehemals Valeant - u.a. Pharmawerte | macumba | M.Minninger | 25.07.24 09:14 | ||
2 | 96 | XOMA | achmadgülcan | macumba | 25.04.21 00:55 | |
| Xoma LTD | Uebelkraehe | 30.11.12 10:12 | ||||
| 2 | 31 | Xoma ist kein Pennystock mehr | CosmicTrade | Reggio Emilia | 17.09.12 16:08 | |
| 3 | 284 | Lieber mal ´ne XOMA, als vom MediaMarkt die Oma ! | baanbruch | CosmicTrade | 12.08.11 15:01 |
